Abstract
Despite the introduction and widespread use in clinical practice of antiTNFα drugs, the current situation of medicamentous therapy in inflammatory bowel diseases cannot be considered as ideal. The short-term anti-inflammatory effects and numerous side-effects, particularly infections, are the drawbacks for the current biological therapy.
The innovative approach includes efforts to find new indications, starting these shortly after the diagnosis and using the current biological agents as a prophylactic therapy against post-operative recurrence of Crohn's disease. A new biological molecule which has already been approved for clinical practice - vedolizumab - mediated its anti-inflammatory effects by inhibiting the migration of white blood cells in the tissue, specifically in the gastrointestinal tract.
There is a reason that its anti-inflammatory effects are not associated with systemic immunosuppression and with infectious complications. The candidates for therapy in clinical practice of Crohn's disease and ulcerative colitis in the future are ustekinumab and tofacitinib.
Key words: biological therapy - vedolizumab - ustekinumab - tofacitinib The author declares he has no potential conflicts of interest concerning drugs, products, or services used in the study. The Editorial Board declares that the manuscript met the ICMJE "uniform requirements" for biomedical papers